Literature DB >> 24061502

The landscape of comparative effectiveness research in rheumatology.

Esi Morgan DeWitt1, Hermine I Brunner1.   

Abstract

Comparative effectiveness research (CER) is a growing area of investigation aimed at determining the most beneficial treatments for patients in view of their clinical characteristics. CER provides personalized treatment information that cannot be obtained from traditional clinical trials. However, many analytical challenges to performing CER remain, particularly in nonexperimental settings. The main obstacles to CER include bias from variation in use of treatments, and heterogeneity in types and quality of data across registries. Increasing standardization of care and consensus among stakeholders regarding CER methodology will strengthen the validity of CER from observational data. Innovations in outcomes measurement, and the ability to repurpose electronic health record data for research will increase the capability to assess treatment effects by CER in clinical practice. Investment in infrastructure, informatics, and data management to sustain high-quality registries, along with engagement of stakeholders to maintain a co-ordinated research agenda, are essential for successful CER in rheumatology.

Entities:  

Mesh:

Year:  2013        PMID: 24061502     DOI: 10.1038/nrrheum.2013.140

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  34 in total

1.  The Patient-Centered Outcomes Research Institute (PCORI) national priorities for research and initial research agenda.

Authors:  Joe V Selby; Anne C Beal; Lori Frank
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

2.  EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology.

Authors:  William G Dixon; Loreto Carmona; Axel Finckh; Merete Lund Hetland; Tore K Kvien; Robert Landewe; Joachim Listing; Paulo J Nicola; Ulrik Tarp; Angela Zink; Johan Askling
Journal:  Ann Rheum Dis       Date:  2010-06-04       Impact factor: 19.103

3.  The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report.

Authors:  Tuhina Neogi; Daniel Aletaha; Alan J Silman; Raymond L Naden; David T Felson; Rohit Aggarwal; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Dinesh Khanna; Tore K Kvien; Timothy Laing; Katherine Liao; Philip Mease; Henri A Ménard; Larry W Moreland; Raj Nair; Theodore Pincus; Sarah Ringold; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

4.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.

Authors:  Kevin E Thorpe; Merrick Zwarenstein; Andrew D Oxman; Shaun Treweek; Curt D Furberg; Douglas G Altman; Sean Tunis; Eduardo Bergel; Ian Harvey; David J Magid; Kalipso Chalkidou
Journal:  J Clin Epidemiol       Date:  2009-05       Impact factor: 6.437

5.  A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries.

Authors:  Jeffrey R Curtis; Archana Jain; Johan Askling; S Louis Bridges; Loreto Carmona; William Dixon; Axel Finckh; Kimme Hyrich; Jeffrey D Greenberg; Joel Kremer; Joachim Listing; Kaleb Michaud; Ted Mikuls; Nancy Shadick; Daniel H Solomon; Michael E Weinblatt; Fred Wolfe; Angela Zink
Journal:  Semin Arthritis Rheum       Date:  2010-08       Impact factor: 5.532

Review 6.  Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis.

Authors:  Monika Schoels; Daniel Aletaha; Josef S Smolen; John B Wong
Journal:  Ann Rheum Dis       Date:  2012-01-30       Impact factor: 19.103

Review 7.  Summary of AHRQ's comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults--an update.

Authors:  Jasvinder A Singh; Davecia R Cameron
Journal:  J Manag Care Pharm       Date:  2012-05

Review 8.  N-of-1 trials in the medical literature: a systematic review.

Authors:  Nicole B Gabler; Naihua Duan; Sunita Vohra; Richard L Kravitz
Journal:  Med Care       Date:  2011-08       Impact factor: 2.983

9.  A proposed 30-45 minute 4 page standard protocol to evaluate rheumatoid arthritis (SPERA) that includes measures of inflammatory activity, joint damage, and longterm outcomes.

Authors:  T Pincus; R H Brooks; L F Callahan
Journal:  J Rheumatol       Date:  1999-02       Impact factor: 4.666

Review 10.  The efficacy of biologic agents in patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor inhibitors: a systematic review.

Authors:  Robert J Moots; Barbara Naisbett-Groet
Journal:  Rheumatology (Oxford)       Date:  2012-09-01       Impact factor: 7.580

View more
  3 in total

Review 1.  Optimizing treatment in paediatric rheumatology--lessons from oncology.

Authors:  Tim Niehues
Journal:  Nat Rev Rheumatol       Date:  2015-04-21       Impact factor: 20.543

2.  Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.

Authors:  Claas H Hinze; Dirk Holzinger; Elke Lainka; Johannes-Peter Haas; Fabian Speth; Tilmann Kallinich; Nikolaus Rieber; Markus Hufnagel; Annette F Jansson; Christian Hedrich; Hanna Winowski; Thomas Berger; Ivan Foeldvari; Gerd Ganser; Anton Hospach; Hans-Iko Huppertz; Kirsten Mönkemöller; Ulrich Neudorf; Elisabeth Weißbarth-Riedel; Helmut Wittkowski; Gerd Horneff; Dirk Foell
Journal:  Pediatr Rheumatol Online J       Date:  2018-01-22       Impact factor: 3.054

3.  Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria.

Authors:  Claas H Hinze; Prasad T Oommen; Frank Dressler; Andreas Urban; Frank Weller-Heinemann; Fabian Speth; Elke Lainka; Jürgen Brunner; Heike Fesq; Dirk Foell; Wolfgang Müller-Felber; Ulrich Neudorf; Christoph Rietschel; Tobias Schwarz; Ulrike Schara; Johannes-Peter Haas
Journal:  Pediatr Rheumatol Online J       Date:  2018-06-25       Impact factor: 3.054

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.